1. Scrip
  2. >>COVID-19

Sanofi Grapples With Pandemic, Growing Clinical Trials, Implementing Acquisitions

 
• By Brenda Sandburg

Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.

Business as usual has been difficult due to COVID-19, but Sanofi has overcome pandemic roadblocks to keep its close to 400 clinical trials on track and integrate new employees following the closing of two acquisitions, John Reed, executive VP and global head of research and development at Sanofi, noted in a discussion at the Stat Summit 19 November.

Reed said the company was able to keep 95% of patients on study by doing direct shipping of investigational product, arranging for at home infusions of I.V. drugs, conducting telemedicine...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

ASCO: J&J Banks On T-Cell Engager’s Safety In Prostate Cancer

 
• By Andrew McConaghie

The company highlighted the KLK2-targeting agent’s safety at ASCO but it may have to rely on combinations to make pasritamig competitive.

ASCO: Regeneron Looks To Become Bigger Immuno-Oncology Player

 
• By Alaric DeArment

The drugmaker presented oral abstracts at the meeting for Libtayo in adjuvant cutaneous squamous-cell carcinoma and linvoseltamab in multiple myeloma.

ASCO: Lupin Presents Early Data On PRMT5 Inhibitor

 
• By Vibha Ravi

ASCO sees the debut of Lupin’s PRMT5 inhibitor candidate LRNP7457, currently in Phase I studies in India. While no drug with this mechanism of action has been approved anywhere so far, several candidates are in clinical trials.